Shionogi Launches Japan's First ADHD Treatment Support App ENDEAVORRIDE
The app represents a new category of digital therapeutics in Japan, offering a clinically tested, insurance-covered game-based option for pediatric ADHD treatment.
Reporting from 1 sources: Automaton.
Shionogi & Co. released the mobile app ENDEAVORRIDE on June 5, a game designed to support childhood ADHD treatment. It is Japan's first app approved as a medical device program for ADHD. A clinical trial showed statistically significant improvement at six weeks, leading to its approval.
Shionogi & Co. released ENDEAVORRIDE on June 5, a mobile game that functions as a digital therapeutic support app for childhood ADHD. The app is Japan's first to be approved as a medical device program for ADHD treatment. It uses a dual-task mechanic-players tilt their device to steer a character while tapping creatures to collect them-designed to activate the prefrontal cortex and reduce inattention, hyperactivity, and impulsivity. A clinical trial of 164 pediatric patients aged 6-17 found that those using ENDEAVORRIDE showed statistically significant improvement at six weeks compared to those receiving standard treatment. The app is available on iOS and requires an activation code from a medical institution.
Synthesized by Yomimono from the 1 cited source below, including Japanese-language reporting where cited, then editorially reviewed before publishing.